Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
Tian J, Song YP, Zhang GC, Wang SF, Chu XX, Chai Y, Wang CL, He AL, Zhang F, Shen XL, Zhang WH, Yang LH, Nie DN, Wang DM, Zhu HL, Gao D, Lou SF, Zhou ZP, Su GH, Li Y, Lin JY, Shi QZ, Ouyang GF, Jing HM, Chen SJ, Li J, Mi JQ. Tian J, et al. Among authors: he al. J Cancer Res Clin Oncol. 2024 Apr 11;150(4):189. doi: 10.1007/s00432-024-05700-x. J Cancer Res Clin Oncol. 2024. PMID: 38605258 Free PMC article. Clinical Trial.
[Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2].
Xu XZ, Liu R, Zhao WH, Yang Y, Liu J, Zhang WG, Bai J, He AL. Xu XZ, et al. Among authors: he al. Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):838-844. doi: 10.3760/cma.j.issn.0253-2727.2023.10.008. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049336 Free PMC article. Chinese.
A multiplexed in vivo approach to identify driver genes in small cell lung cancer.
Lee MC, Cai H, Murray CW, Li C, Shue YT, Andrejka L, He AL, Holzem AME, Drainas AP, Ko JH, Coles GL, Kong C, Zhu S, Zhu C, Wang J, van de Rijn M, Petrov DA, Winslow MM, Sage J. Lee MC, et al. Among authors: he al. Cell Rep. 2023 Jan 31;42(1):111990. doi: 10.1016/j.celrep.2023.111990. Epub 2023 Jan 13. Cell Rep. 2023. PMID: 36640300 Free PMC article.
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
Wang BY, Zhao WH, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Zhuang QC, Fan F, Zhang WG, He AL, Liu J. Wang BY, et al. Among authors: he al. J Med Case Rep. 2022 Dec 11;16(1):459. doi: 10.1186/s13256-022-03636-9. J Med Case Rep. 2022. PMID: 36496425 Free PMC article.
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).
Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, Jin SW, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Zhang H, Bai J, Xu Y, Zhu H, Du J, Jiang H, Fan XH, Li JY, Hou J, Chen Z, Zhang WG, Mi JQ, Chen SJ, He AL. Zhao WH, et al. Among authors: he al. J Hematol Oncol. 2022 Jul 6;15(1):86. doi: 10.1186/s13045-022-01301-8. J Hematol Oncol. 2022. PMID: 35794616 Free PMC article. Clinical Trial.
61 results